Table 1.
Baseline characteristics of the study population
| Placebo group (n = 45) | BMC group (n = 55) | P-value | |
|---|---|---|---|
| Age (year), mean ± SD | 56.7 ± 10.7 | 56.4 ± 10.4 | 0.89 |
| Sex (M/F), n) | 41/4 | 46/9 | 0.27 |
| Ethnicity (Caucasian) (n, %) | 36 (80%) | 47 (85.5%) | 0.82 |
| Medical history | |||
| Hypertension (n, %) | 12 (26.7%) | 24 (43.6%) | 0.080 |
| Hypercholesterolaemia (n, %) | 10 (22.2%) | 19 (34.5%) | 0.18 |
| Diabetes mellitus (n, %) | 4 (8.8%) | 6 (10.9%) | 0.74 |
| Active smoker (n, %) | 24 (53.3%) | 27 (49.0%) | 0.74 |
| Previous MI (n, %) | 1 (2.2%) | 1 (1.8%) | 0.89 |
| Previous PCI (n, %) | 0 (0%) | 1 (1.8%) | 0.37 |
| Family history (n, %) | 13 (28.8%) | 17 (30.9%) | 0.83 |
| Medical therapy | |||
| Aspirin (n, %) | 45 (100%) | 55 (100%) | 1.0 |
| Clopidogrel (n, %) | 39 (86.7%) | 50 (90.9%) | 0.68 |
| Prasugrel (n, %) | 4 (8.9%) | 3 (5.5%) | 0.70 |
| Ticagrelor (n, %) | 2 (4.4%) | 2 (3.6%) | 1.0 |
| Heparin (n, %) | 40 (88.9%) | 50 (90.9%) | 0.75 |
| Bivalirudin (n, %) | 5 (11.1%) | 5 (9.1%) | 0.75 |
| GP iib/iiia inhibitors (n, %) | 33 (73%) | 44 (80%) | 0.63 |
| DES used (n, %) | 32 (71%) | 36 (65%) | 0.29 |
| Concomitant PCI performed (n, %) | 1 (2.2%) | 3 (5.5%) | 0.62 |
| Baseline observations | |||
| Blood pressure (diastolic/systolic), mean | 138.6/85.6 | 138.0/83.9 | 0.89/0.62 |
| Pulse (bpm), mean ± SD | 84.5 ± 26.1 | 80.3 ± 19.8 | 0.44 |
| BMI (kg/m2), mean ± SD | 27.1 ± 4.3 | 26.7 ± 3.1 | 0.58 |
| CCS >1 (n, %) | 1 (2.2%) | 5 (9.1%) | 0.22 |
| NYHA >I (n, %) | 3 (6.7%) | 4 (7.3%) | 1.0 |
| Angiographic findings | |||
| BARI score (%) | 35.6 (33.0–38.0) | 35.6 (33.1–38.1) | 0.98 |
| APPROACH score (%) | 37.1 (34.9–39.3) | 38.5 (36.4–40.6) | 0.37 |
| TIMI flow <2 (n, %) | 35 (77.8%) | 38 (60%) | 0.37 |
| Timings | |||
| Chest pain to PCI (min), median (IQR) | 193.0 (145.5–320.5) | 233 (155.0–348) | 0.23 |
| Door to PCI time (min), median (IQR) | 36.0 (26.0–55.5) | 40.0 (32.0–58.0) | 0.22 |
| PCI to BM aspiration time (min), median (IQR) | 230.0 (112.0–966.0) | 172.0 (105.0–976.0) | 0.61 |
| PCI to reinfusion (min), median (IQR) | 583.0 (458.0–1276) | 532.0 (403.0–1312) | 0.74 |
| BM aspiration to infusion (min), median (IQR) | 313.0 (287.0–374.0) | 323.0 (290.0–370.0) | 0.41 |
| Baseline LV function (CMR/CT) | |||
| LVEF (%) | 48.9 (45.9–51.9) | 47.8 (45.2–50.3) | 0.56 |
| LVEDV (mL) | 159.6 (149.5–169.7) | 154.5 (145.5–163.4) | 0.44 |
| LVESV (mL) | 81.4 (74.0–88.8) | 81.8 (74.7–89.0) | 0.93 |
Values are mean (95% CI).
BMI, body mass index (weight (kg)/height2 (m)); BM, bone marrow; BARI, Bypass Angioplasty Revascularization Investigation Myocardial Jeopardy Index; APPROACH, Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease score; DES, drug eluting stent; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume.